Humanigen's mAb improves outcomes in hospitalized COVID-19 patients

By The Science Advisory Board staff writers

March 29, 2021 -- Humanigen is highlighting results from a phase III trial that show that its monoclonal antibody (mAb), lenzilumab, improves outcomes in hospitalized COVID-19 patients by keeping them off mechanical ventilators.

The study found that patients who received the drug in combination with other treatments including steroids and remdesivir had a 54% greater relative likelihood of survival without the need for mechanical ventilation compared with patients receiving placebo and other treatments.

Humanigen plans to submit an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for lenzilumab.

Humanigen awarded 2 patents against immunotherapy toxicities
The U.S. Patent and Trademark Office has awarded Humanigen two patents for the use of lenzilumab.
Humanigen, Avid enter COVID-19 therapy manufacturing agreement
Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production...
Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...
Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...
Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter